ALGS · Insider Trading
Aligos Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ALGS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Margarita Chavez | Director | A | +5,860 deriv. | — |
| 2026-06-29 | Bridget A Martell | Director | A | +5,860 deriv. | — |
| 2026-06-29 | Heather Preston | Director | A | +5,860 deriv. | — |
| 2026-06-29 | Carole Nuechterlein | Director | A | +5,860 deriv. | — |
| 2026-06-29 | Peter Hirth | Director | A | +5,860 deriv. | — |
| 2026-06-29 | James Paul Scopa | Director | A | +5,860 deriv. | — |
| 2026-03-11 | Julian A. Symons | See Remarks | A | +23,310 deriv. | — |
| 2026-03-11 | Nikhil Aneja | Principal Accounting Officer | A | +9,450 deriv. | — |
| 2026-03-11 | Lawrence Blatt | President and CEO | A | +105,840 deriv. | — |
| 2026-03-11 | Lesley Ann Calhoun | See Remarks | A | +37,485 deriv. | — |
| 2025-07-18 | Lawrence Blatt | President and CEO | A | +179,800 deriv. | — |
| 2025-07-18 | Julian A. Symons | See Remarks | A | +16,000 deriv. | — |
| 2025-07-18 | Lesley Ann Calhoun | See Remarks | A | +40,185 deriv. | — |
| 2025-06-26 | Margarita Chavez | Director | A | +5,860 deriv. | — |
| 2025-06-26 | Bridget A Martell | Director | A | +5,860 deriv. | — |
| 2025-06-26 | Peter Hirth | Director | A | +5,860 deriv. | — |
| 2025-06-26 | Carole Nuechterlein | Director | A | +5,860 deriv. | — |
| 2025-06-26 | James Paul Scopa | Director | A | +5,860 deriv. | — |
| 2025-06-26 | Heather Preston | Director | A | +5,860 deriv. | — |
| 2025-03-04 | Lawrence Blatt | President and CEO | A | +140,103 deriv. | — |
| 2025-03-04 | Lesley Ann Calhoun | See Remarks | A | +47,271 deriv. | — |
| 2025-03-04 | Julian A. Symons | See Remarks | A | +21,693 deriv. | — |
| 2024-10-10 | Hardean Achneck | Chief Medical Officer | A | +75,000 deriv. | — |
| 2024-09-06 | Julian A. Symons | See Remarks | A | +10,880 deriv. | — |
| 2024-09-06 | Lawrence Blatt | Chief Executive Officer | A | +33,920 deriv. | — |
| 2024-09-06 | Lesley Ann Calhoun | — | A | +10,880 deriv. | — |
| 2024-08-09 | Margarita Chavez | Director | A | +120,000 deriv. | — |
| 2024-08-09 | Heather Preston | Director | A | +120,000 deriv. | — |
| 2024-06-28 | James Paul Scopa | Director | A | +60,000 deriv. | — |
| 2024-06-28 | Peter Hirth | Director | A | +60,000 deriv. | — |
| 2024-06-28 | Bridget A Martell | Director | A | +60,000 deriv. | — |
| 2024-06-28 | Carole Nuechterlein | Director | A | +60,000 deriv. | — |
| 2024-03-04 | Julian A. Symons | See Remarks | A | +72,000 deriv. | — |
| 2024-03-04 | Matthew W. McClure | Chief Medical Officer | A | +72,000 deriv. | — |
| 2024-03-04 | Lawrence Blatt | Chief Executive Officer | A | +965,435 deriv. | — |
| 2024-03-04 | Lesley Ann Calhoun | — | A | +308,940 deriv. | — |
| 2024-02-28 | Peter Hirth | Director | MIXED | −10,589 deriv. | — |
| 2024-02-28 | Carole Nuechterlein | Director | MIXED | −10,589 deriv. | — |
| 2024-02-28 | Jack Nielsen | Director | MIXED | −10,589 deriv. | — |
| 2024-02-28 | Julian A. Symons | See Remarks | MIXED | −178,680 deriv. | — |
| 2024-02-28 | Bridget A Martell | Director | MIXED | −21,177 deriv. | — |
| 2024-02-28 | Lawrence Blatt | Chief Executive Officer | MIXED | −433,150 deriv. | — |
| 2024-02-28 | James Paul Scopa | Director | MIXED | −21,177 deriv. | — |
| 2024-02-28 | Lesley Ann Calhoun | — | MIXED | −161,906 deriv. | — |
| 2024-02-28 | Matthew W. McClure | Chief Medical Officer | MIXED | −213,302 deriv. | — |
| 2023-10-27 | James Paul Scopa | Director | A | +183,083 | +$138.56K |
| 2023-10-27 | Lawrence Blatt | Chief Executive Officer | A | +610,277 | +$461.86K |
| 2023-10-27 | Carole Nuechterlein | Director | Buy | +7,933,601 | +$6.00M |
| 2023-09-12 | Lawrence Blatt | Chief Executive Officer | A | +150,000 deriv. | — |
| 2023-09-12 | Matthew W. McClure | Chief Medical Officer | A | +48,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Carole Nuechterlein | Director | 441,038 | $2.05M |
| Lawrence Blatt | President and CEO | 78,440 | $364.75K |
| Julian A. Symons | See Remarks | 15,763 | $73.30K |
| James Paul Scopa | Director | 7,323 | $34.05K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALGS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.